SELLAS Life Sciences Group, Inc.(NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

SELLAS Life Sciences Group, Inc.(NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

GlobeNewswire Inc | Oct 7, 2021 09:14AM EDT

October 07, 2021

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.(NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:

-- Laguna Biotech CEO Forum 2021 to be held at the Montage Laguna Beach hotel in Laguna Beach, CA on October 10-12, 2021. -- A.G.P./Alliance Global Partners Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.

For more information about the conferences, or to schedule a one-on-one meeting with SELLAS management, please contact your representative directly, or send an email toA.G.P./Alliance Global Partners at agpevents@allianceg.com, or KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS lead product candidate,galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includestriple negative breast cancer (TNBC) patients, following the standard of care.

For more information on SELLAS, please visitwww.sellaslifesciences.com.

Investor ContactsAllison SossKCSA Strategic Communications212.896.1267SELLAS@kcsa.com

Media ContactsRaquel ConaKCSA Strategic Communications212.896.1204SELLAS@kcsa.com